BioFuture 2026 Gathers Biopharma Leaders to Tackle Innovation Barriers

The two-day conference at Cure, 345 Park Avenue South, serves as a high-level forum for executives from Johnson & Johnson, Regeneron Pharmaceuticals, and Schrödinger to navigate the intersection of artificial intelligence, neuroscience, and MedTech. Beyond traditional main-stage presentations, the event prioritizes direct engagement through industry analyst-led Spotlight Panels and a Seed Showcase designed to provide early-stage firms with immediate investor feedback.

Sara Jane Demy, CEO of Demy-Colton, emphasizes that the industry’s greatest challenges extend beyond the laboratory. The program explicitly targets the mechanics of translation, examining how policy, regulation, and investment strategies dictate whether a discovery reaches the clinic or stalls in development. Key sessions will interrogate the sustainability of biotech funding and the ethical tensions inherent in balancing healthcare as a fundamental right against the demands of a commercial business model. The gathering concludes with a focus on AI-driven drug discovery and global market dynamics, including China’s evolving role in the biotech ecosystem.